Li Jia
Zunyi Medical College
6 Papers
Li Jia is an academic researcher from Zunyi Medical College. The author has contributed to research in topics: Biology & Immune system. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
miR-30 Family: A Promising Regulator in Development and Disease.
TL;DR: This review aims to clarify the current progress on the regulating role of miR-30 family in tissues and organs development and related disease and highlight their research prospective in the future.
Nanostructured Lipid Carriers for MicroRNA Delivery in Tumor Gene Therapy
TL;DR: Recent research progress on NLCs for miRNA delivery in tumor gene therapy and prospective applications is reviewed.
Tolerogenic dendritic cells induced the enrichment of CD4+Foxp3+ regulatory T cells via TGF-β in mesenteric lymph nodes of murine LPS-induced tolerance model.
TL;DR: The data provided an unknown phenomenon that the total cell number of CD4+Foxp3+Tregs significantly increased in MLNs in endotoxin tolerance, which was related to MLN-resident TGF-β secreting CD11c+DCs, providing a new fundamental basis for the understanding on the potential roles of MLn-resident immune cells in the development of endotoxinolerance.
18
TCR repertoire landscape reveals macrophage-mediated clone deletion in endotoxin tolerance
Juanjuan Zhao,Li Jia,Yijing Tao,Xu Zhao,Jing Yang,Yanxin Lu,Yaping Yan,Ling Mao,Lin Hu,Jiancong Lu,Mengmeng Guo,Chao Chen,Ya Zhou,Zhenke Wen,Zhixu He,Lin Xu +15 more
TL;DR: In this paper , high-throughput sequencing was performed to analyze the characteristics and changes of CD4+SP TCRβ CDR3 repertoires with respect to V direct to J rearrangement during the ET induction.
2
Relieving immunosuppression by Endo@PLT targeting anti-angiogenesis to improve the efficacy of immunotherapies.
Chao Chen,Yijie Tang,Hao Huang,Li Jia,Lingzi Feng,Jia-Xi Zhao,Hao Zhang,Jiang He,Lingchi Ding,Dong-Lin Xia +9 more
TL;DR: A tumor-targeting drug delivery system composed of Endo-loaded platelets (Endo@PLT) was developed to relieve immunosuppression by achieving tumor vascular normalization, achieving excellent PD-1 immunotherapy in vivo.